Praluent and Repatha belong a class of injectable biotech drugs called PCSK9 inhibitors that dramatically lower bad LDL cholesterol and reduce the risk of heart attacks and death PositiveNEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug